Amyloid Beta 42 Test

Amyloid beta 42 (often shortened to Aβ42) is a small protein fragment produced when a larger protein, called amyloid precursor protein, is broken down in the brain. While this process occurs naturally, Aβ42 is particularly prone to clumping together. These clumps, called amyloid plaques, are a defining feature of Alzheimer’s disease, the most common cause of dementia.

Compared with its shorter relative Aβ40, Aβ42 is more likely to stick to itself and form long chains, oligomers, and eventually plaques. These aggregates are not harmless byproducts; they interfere with how brain cells communicate, disturb calcium balance inside neurons, and can even form pore-like channels that damage cells. Aβ42 also binds tightly to receptors such as the α7 nicotinic acetylcholine receptor, which is important for memory, further contributing to cognitive decline.

The toxicity of Aβ42 does not only come from the visible plaques seen under the microscope. Smaller, soluble clumps (called oligomers) are now thought to be especially harmful, triggering inflammation and cell death before large plaques are even present. This explains why memory and thinking problems can begin long before Alzheimer’s disease is formally diagnosed.

From a diagnostic standpoint, Aβ42 has become a central biomarker. In the cerebrospinal fluid (CSF), lower levels of Aβ42 indicate that much of it has aggregated into plaques in the brain. In contrast, blood tests often measure the ratio of Aβ42 to Aβ40, since this corrects for overall protein production and improves accuracy.

That said, changes in Aβ42 levels are not always caused by Alzheimer’s disease alone. Metabolic conditions such as obesity and insulin resistance can also influence circulating Aβ42, linking this biomarker to broader aspects of brain and metabolic health.